BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-158@catalystbrief.girapphe.com
DTSTAMP:20261118T181603Z
LAST-MODIFIED:20261118T181603Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: ModernaTX\, Inc. — mRNA-1403 [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Investigate the Safety a
 nd Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Preven
 tion of Acute Gastroenteritis.\nSource: https://clinicaltrials.gov/study/N
 CT06592794\nhttps://catalystbrief.girapphe.com/e/158?lang=en\nNot investme
 nt advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/158?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
